04 octubre 2016

PharmaMar y Boryung Pharmaceutical Firman Acuerdo de Licencia para la Venta de Aplidin en Corea del Sur para el Tratamiento de Myeloma Multiple .

Boryung Pharma to Commercialize Aplidin from Spain.

PharmaMar und Boryung Pharm Sign gehen einen Lizenzvertrag über Aplidin® (Plitidepsin) in Korea ein .

Published: 2016-10-04 14:14
Updated: 2016-10-04 14:14

Boryung Pharmaceutical(003850) reported on Oct. 4 that it has signed a technology introduction contract with PharmaMar of Spain for rights to launch and commercialize Aplidin, a treatment option for multiple myeloma, in Korea.

By Yun Jeong-hyeon